SCHEMBL5183236

SCHEMBL5183236

O=C(O)c1ccc2cncc(Nc3cccc(C(F)(F)F)c3)c2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 6/20 0.50
AKR1C3 P42330 2/20 0.47
AKR1C2 P52895 2/20 0.47
TAS2R14 Q9NYV8 1/20 0.47
MEN1 O00255 1/20 0.46
GMNN O75496 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
TTR P02766 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
PKM P14618 1/20 0.46
NFKB1 P19838 1/20 0.46
UGT1A1 P22309 1/20 0.46
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
PMP22 Q01453 1/20 0.46
DHODH Q02127 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4581123 0.86 TAS2R14 (0.43) AKR1C3AKR1C2TAS2R14TRPV1MMP2
SCHEMBL4580845 0.83 MMP2 (0.46) KMT2AMMP2
SCHEMBL4580266 0.80 POLB (0.53) MEN1ALDH1A1LMNAKMT2ATDP1
SCHEMBL4582757 0.78 GSK3A (0.42) MEN1ALDH1A1LMNAPKMKMT2A
SCHEMBL14394250 0.78 HDAC3 (0.38) MPOAKR1C3AKR1C2MEN1LMNA
SCHEMBL1724686 0.78 CCNC (0.49) AKR1C3AKR1C2MEN1ALDH1A1KMT2A
SCHEMBL4579533 0.76 ADRA2A (0.47) MEN1LMNAKMT2AMMP2
SCHEMBL4581447 0.76 CCNC (0.39) MEN1ALDH1A1LMNADHODHKMT2A
SCHEMBL18286208 0.75 AURKA (0.60) MPOAKR1C3AKR1C2MEN1GMNN
SCHEMBL4580442 0.74 P4HTM (0.43) AKR1C3AKR1C2PTGS1PTGS2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US claimed
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives SERENEX, INC. 2006-02-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives CCNA1, FOXM1, CCNA2 MPO 194/4885AKR1C3 121/4885AKR1C2 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.